March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.
Tag: innovation
FACIT announces follow-on investments in Xpan Inc. and Nanology Labs through Compass Rose Fund
January 28, 2020 – January 28, 2020 – Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund.